GURUFOCUS.COM » STOCK LIST » USA » NAS » C4 Therapeutics Inc (NAS:CCCC) » Definitions » ROE % Adjusted to Book Value
Switch to:

C4 Therapeutics (NAS:CCCC) ROE % Adjusted to Book Value

: -48.97% (As of Dec. 2022)
View and export this data going back to 2020. Start your Free Trial

C4 Therapeutics's ROE % for the quarter that ended in Dec. 2022 was -48.97%. C4 Therapeutics's PB Ratio for the quarter that ended in Dec. 2022 was 1.00. C4 Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2022 was -48.97%.


C4 Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for C4 Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4 Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
- - -15.47 -6.23 -37.76

C4 Therapeutics Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
ROE % Adjusted to Book Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.95 -10.35 -28.91 -28.57 -48.97

Competitive Comparison

For the Biotechnology subindustry, C4 Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

C4 Therapeutics ROE % Adjusted to Book Value Distribution

For the Biotechnology industry and Healthcare sector, C4 Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where C4 Therapeutics's ROE % Adjusted to Book Value falls in comparison to its industry or sector. The grey bar indicates the ROE % Adjusted to Book Value's extreme value range as defined by GuruFocus.



C4 Therapeutics ROE % Adjusted to Book Value Calculation

C4 Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-37.76% / 1.00
=-37.76%

C4 Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-48.97% / 1.00
=-48.97%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


C4 Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of C4 Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


C4 Therapeutics (NAS:CCCC) Business Description

C4 Therapeutics logo
Traded in Other Exchanges
N/A
Address
490 Arsenal Way, Suite 200, Watertown, MA, USA, 02472
C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.
Executives
Laura Bessen director 4747 EXECUTIVE DRIVE, SUITE 1150, SAN DIEGO CA 92121
Donna Roy Grogan director 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Scott N Boyle officer: Chief Business Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Kelly Schick officer: Chief People Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Utpal Koppikar director C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Lauren White officer: Chief Financial Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Glenn Dubin director C/O HIGHBRIDGE CAPITAL MANAGEMENT, LLC, 40 WEST 57TH STREET, 32ND FLOOR, NEW YORK NY 10019
Marc A Cohen director, 10 percent owner, officer: Chief Executive Officer 1000 WILSON BLVD. #1800, ARLINGTON VA 22209
Alain J Cohen director, 10 percent owner 7255 WOODMONT AVE, BETHESDA MD 20814
Elena Prokupets director C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Kenneth Carl Anderson director C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Malcolm Salter director C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Jolie Siegel officer: Chief Legal Officer C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Stewart Fisher officer: Chief Scientific Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Laura Jean Wahlberg officer: See Remarks C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472

C4 Therapeutics (NAS:CCCC) Headlines

From GuruFocus

Other Sources